| Objective To investigate the therapeutic effect and side effect of recombinant human prourokinase(Pro- UK) on the patients with acute myocardial infarction in china.MethodsA total of 68 cases of acute myocardial infarction treated by thrombolytic agents within 6 hours after onset were divided randomly into Pro - UK group(n=43) and urokinase(UK) group(n = 25).In Pro - UK group,20mg Pro - UK was used by intravenous injection within 3 minutes,then 30mg Pro - UK was injection into vein within 30 minutes.In UK group,1.5 million units UK was used by intravenous injection within 30 minutes.The dilation of infarct - related coronary artery was evaluated by coronary angiography.Early heart events,bleeding and adverse reactions were alse observed.Results①The total reopening rates of infarct- related coronary artery(TIMI grade 2 and 3 flow) were 76.7%in Pro-UK group and 52.2%in UK group,respectively(P＜0.05).②There was no mortality in the UK group.However in the Pro - UK group,one patient(2.3%) experienced mortality, but there were not significantly different between them(P＞0.05).The occurrence rate of heart failure and postinfarction angina of Pro - UK group was decreased than that of UK group,but there were not significantly different between them(2.3%vs4%,P＞0.05;11. 6%vs32%,P＞0.05).Reinfarction was not occurred in both group during hospital.③Occurrence of hyporrhea was decreased more significantly in the Pro - UK than in the UK(P＜0.05),but there were no intracranial hemorrhage in both group.④There were no adverse reaction occurred in both group.Conclusion Pro - UK is safe and effective for the patients with acute myocardial infarction. |
PDF Full Text Request